The calprotectin testing market is capturing a valuation of US$ 201.1 billion in 2023 and is predicted to reach US$ 360.2 billion by 2033. The market is registering a CAGR of 6% during the forecast period.
The market is driven by various factors, including:
Lack of Awareness and Low Standardized Product Limit the Market Growth
Various factors restrain market growth are:
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 6% |
| Market Valuation (2023) | US$ 201.1 billion |
| Market Valuation (2033) | US$ 360.2 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market experienced steady growth between 2018 and 2022. The market was valued at US$ 190.5 billion in 2022, with a CAGR of 5.3% between 2018 and 2022. A surge in chronic patients, increasing demand for non-invasive diagnostic tools, and growing advanced technology have driven the market size.
The market has faced various challenges, such as limited awareness, low-quality tools, and high competition. The various end-use sectors, such as hospitals, specialty clinics, and others, continuously grow the market revenue during the forecast period. Healthcare manufacturers are developing advanced tools to detect and monitor patients' chronic conditions.
Based on test kits, calprotectin ELISA test kits are estimated to dominate the global market by securing a share of 90.46% during the forecast period. The laboratory's adoption of calprotectin ELISA test kits is increasing to detect and qualify biological samples. These kits help measure the calprotectin level, advancing the market growth.
The demand for calprotectin ELISA test kits is rising due to their ability to collect multiple samples and ease to use with high sensitivity. The growing popularity of these devices among healthcare professionals is fueling the market size. The manufacturers are distributors offering multiple kits with their respective uses, and benefits are advancing the market opportunities.
Based on indication, irritable bowel syndrome is anticipated to lead the global market by registering a share of 79% during the forecast period. Irritable bowel syndrome is a prime indication segment that affects the large intestine. The rising prevalence of irritable bowel syndrome surges the demand for calprotectin testing.
Principal Consultant
| Countries | Projected Value (2023 to 2033) |
|---|---|
| United States | 25.7% |
| Germany | 3% |
| Japan | 3.1% |
| Australia | 5.6% |
| China | 7.8% |
| India | 8.7% |
| United Kingdom | 6.2% |
The United States is estimated to dominate the global market by securing a share of 25.7% during the forecast period. The increasingly advanced testing technology and growing patient awareness fuel the country's market size. The growth in gastrointestinal disorders and chronic diseases is increasing the adoption of calprotectin testing in the healthcare sector.
Healthcare manufacturers are developing advanced testing equipment to monitor patients' diseases and enhance the performance of checkups. These manufacturers offer a variety of testing tools to monitor the diagnostic condition of patients. Additionally, provide better services expanding the United States calprotectin testing market.
Germany is one of the significant countries in the global market that secure a share of 3% during the forecast period. Various factors are driving the German market are:
Japan is one of the significant countries in the global market, capturing a share of 3.1% during the forecast period. The rising prevalence of inflammatory bowel disease is fueling the market growth in Japan. For Instance, around 2,00,000 people have been affected by inflammatory bowel disease recently.
The aging population and chronic patients are increasing the demand for calprotectin testing in Japan. The surging demand for diagnostic tests among patients is increasing the adoption of these testing tools. The manufacturers in Japan are investing in research and development activities to upsurge the medical field. Several Japanese companies are improving testing devices to provide accuracy in testing.
The increasing aging population and strong research activities are innovating unique products that satisfy healthcare providers' and patients' requirements. These factors are contributing to uplifting Japan's calprotectin testing market.
With the following steps, the manufacturers can expand the global market are:
These are a few steps on which the manufacturers can expand the global market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Several key players highly influence the market. The key players are developing unique and advanced testing devices to detect and monitor patients' chronic diseases. They are investing in research and development activities and offer better solutions with advanced technologies.
These players are fueling the healthcare sector by increasing their services as per consumers' needs. The players are adopting various marketing tactics to enhance the global market size. These marketing strategies are collaborations, acquisitions, mergers, partnerships, agreements, and product launches.
Other Essential Players in the Market are:
Recent Development in the Global Market are:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | The United States, The United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Test Kit, Sample, Indication, End Use, Region |
| Key Companies Profiled | Actim Oy; Calpro AS; BÜHLMANN Laboratories AG; EagleBio; CerTest Biotec S.L.; EUROIMMUN Medizinische Labordiagnostika AG; Boditech Med Inc.; Biohit Oyj; American Laboratory Products Company, Ltd.; DIAsource ImmunoAssays S.A; R-Biopharm AG.; Abbexa; AccuBio Tech Co., Ltd.; Screen Italia Srl.; Hangzhou Biotest Biotech Co., Ltd; Thermo Fisher Scientific; Epitope Diagnostics, Inc.; Elabscience Biotechnology Inc; Vitassay Healthcare, S.L.U.; Beckman Coulter Inc.; DiaSorin |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The 2023 market value is US$ 201.1 billion.
Until 2033, the market will rise at a 6% CAGR.
By 2033, the market will total US$ 360.2 billion.
Rising gastrointestinal disorder diagnoses propel market growth.
North America will be a highly lucrative market.
1. Executive Summary | Calprotectin Testing Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Kits 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Test Kits, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Kits, 2023 to 2033 5.3.1. Calprotectin ELISA 5.3.2. Calprotectin Rapid 5.4. Y-o-Y Growth Trend Analysis By Test Kits, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Test Kits, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sample 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Sample, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sample, 2023 to 2033 6.3.1. Stool 6.3.2. Plasma 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By Sample, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Sample, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033 7.3.1. Irritable Bowel Syndrome (IBS) 7.3.2. Ulcerative Colitis 7.3.3. Crohn's Disease 7.3.4. Colorectal Cancer 7.4. Y-o-Y Growth Trend Analysis By Indication , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033 8.3.1. Hospitals 8.3.2. Diagnostic Laboratories 8.3.3. Specialty Clinics 8.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. United States of America 10.2.1.2. Canada 10.2.2. By Test Kits 10.2.3. By Sample 10.2.4. By Indication 10.2.5. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Test Kits 10.3.3. By Sample 10.3.4. By Indication 10.3.5. By End-User 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Test Kits 11.2.3. By Sample 11.2.4. By Indication 11.2.5. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Test Kits 11.3.3. By Sample 11.3.4. By Indication 11.3.5. By End-User 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Test Kits 12.2.3. By Sample 12.2.4. By Indication 12.2.5. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Test Kits 12.3.3. By Sample 12.3.4. By Indication 12.3.5. By End-User 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Test Kits 13.2.3. By Sample 13.2.4. By Indication 13.2.5. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Test Kits 13.3.3. By Sample 13.3.4. By Indication 13.3.5. By End-User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Test Kits 14.2.3. By Sample 14.2.4. By Indication 14.2.5. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Test Kits 14.3.3. By Sample 14.3.4. By Indication 14.3.5. By End-User 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Test Kits 15.2.3. By Sample 15.2.4. By Indication 15.2.5. By End-User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Test Kits 15.3.3. By Sample 15.3.4. By Indication 15.3.5. By End-User 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Test Kits 16.2.3. By Sample 16.2.4. By Indication 16.2.5. By End-User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Test Kits 16.3.3. By Sample 16.3.4. By Indication 16.3.5. By End-User 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. United States of America 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Test Kits 17.1.2.2. By Sample 17.1.2.3. By Indication 17.1.2.4. By End-User 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Test Kits 17.2.2.2. By Sample 17.2.2.3. By Indication 17.2.2.4. By End-User 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Test Kits 17.3.2.2. By Sample 17.3.2.3. By Indication 17.3.2.4. By End-User 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Test Kits 17.4.2.2. By Sample 17.4.2.3. By Indication 17.4.2.4. By End-User 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Test Kits 17.5.2.2. By Sample 17.5.2.3. By Indication 17.5.2.4. By End-User 17.6. United Kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Test Kits 17.6.2.2. By Sample 17.6.2.3. By Indication 17.6.2.4. By End-User 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Test Kits 17.7.2.2. By Sample 17.7.2.3. By Indication 17.7.2.4. By End-User 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Test Kits 17.8.2.2. By Sample 17.8.2.3. By Indication 17.8.2.4. By End-User 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Test Kits 17.9.2.2. By Sample 17.9.2.3. By Indication 17.9.2.4. By End-User 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Test Kits 17.10.2.2. By Sample 17.10.2.3. By Indication 17.10.2.4. By End-User 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Test Kits 17.11.2.2. By Sample 17.11.2.3. By Indication 17.11.2.4. By End-User 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Test Kits 17.12.2.2. By Sample 17.12.2.3. By Indication 17.12.2.4. By End-User 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Test Kits 17.13.2.2. By Sample 17.13.2.3. By Indication 17.13.2.4. By End-User 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Test Kits 17.14.2.2. By Sample 17.14.2.3. By Indication 17.14.2.4. By End-User 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Test Kits 17.15.2.2. By Sample 17.15.2.3. By Indication 17.15.2.4. By End-User 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Test Kits 17.16.2.2. By Sample 17.16.2.3. By Indication 17.16.2.4. By End-User 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Test Kits 17.17.2.2. By Sample 17.17.2.3. By Indication 17.17.2.4. By End-User 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Test Kits 17.18.2.2. By Sample 17.18.2.3. By Indication 17.18.2.4. By End-User 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Test Kits 17.19.2.2. By Sample 17.19.2.3. By Indication 17.19.2.4. By End-User 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Test Kits 17.20.2.2. By Sample 17.20.2.3. By Indication 17.20.2.4. By End-User 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Test Kits 17.21.2.2. By Sample 17.21.2.3. By Indication 17.21.2.4. By End-User 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Test Kits 18.3.3. By Sample 18.3.4. By Indication 18.3.5. By End-User 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Actim Oy 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Calpro AS 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. BÜHLMANN Laboratories AG 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. EagleBio 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. CerTest Biotec S.L. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. EUROIMMUN Medizinische Labordiagnostika AG 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Boditech Med Inc. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Biohit Oyj 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. American Laboratory Products Company, Ltd. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. DIAsource ImmunoAssays S.A 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. R-Biopharm AG. 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Abbexa 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 19.1.13. AccuBio Tech Co., Ltd. 19.1.13.1. Overview 19.1.13.2. Product Portfolio 19.1.13.3. Profitability by Market Segments 19.1.13.4. Sales Footprint 19.1.13.5. Strategy Overview 19.1.13.5.1. Marketing Strategy 19.1.14. Screen Italia Srl. 19.1.14.1. Overview 19.1.14.2. Product Portfolio 19.1.14.3. Profitability by Market Segments 19.1.14.4. Sales Footprint 19.1.14.5. Strategy Overview 19.1.14.5.1. Marketing Strategy 19.1.15. Hangzhou Biotest Biotech Co., Ltd 19.1.15.1. Overview 19.1.15.2. Product Portfolio 19.1.15.3. Profitability by Market Segments 19.1.15.4. Sales Footprint 19.1.15.5. Strategy Overview 19.1.15.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Calprotectin Testing Market
